<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00351416</url>
  </required_header>
  <id_info>
    <org_study_id>2003-P-001895</org_study_id>
    <secondary_id>Sundry Department Fund</secondary_id>
    <nct_id>NCT00351416</nct_id>
  </id_info>
  <brief_title>Letrozole Treatment in Normal and GnRH Deficient Women</brief_title>
  <official_title>Letrozole Treatment in Normal and GnRH Deficient Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study involves the use of the drugs Letrozole, GnRH, and NAL-GLU GnRH
      antagonist. Letrozole is a drug that is approved by the U.S. Food and Drug Administration
      (FDA) for use in breast cancer treatment that has been found to block the formation of
      estrogen. The NAL-GLU GnRH antagonist is a drug that temporarily blocks the action of GnRH.
      GnRH is a hormone that the body makes that stimulates other hormones that then control the
      function of the ovary.

      The purpose is to study the effects of the administration of letrozole in women with GnRH
      deficiency at the same time that they receive gonadotropin-releasing hormone (GnRH). In
      addition, administration of letrozole and NAL-GLU GnRH antagonist in healthy women with
      normal menstrual cycles will be done to evaluate the role of estrogen in the control of the
      hormone FSH, or Follicle Stimulating Hormone, in the female reproductive cycle. A better
      understanding of FSH control may help in the development of new treatments for women with
      difficulty conceiving.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The negative feedback control of FSH is crucial for the precise regulation of follicular
      development in the female. An important component of this feedback is exerted by estrogen.
      Letrozole will be used to block aromatase and therefore estradiol production in normal and
      GnRH deficient females. These studies will dissect the relative roles of estradiol and
      inhibin on FSH secretion at the pituitary and hypothalamus.

      The aromatase inhibitors block aromatization of androgens to estrogens, allowing us to
      examine the relative contribution of estradiol and the inhibins to FSH regulation. The use of
      a submaximal dose of a GnRH antagonist will allow us to estimate the overall amount of GnRH
      secreted (hypothalamic contribution) with and without aromatase inhibition.

      A more thorough understanding of estrogen and inhibin feedback on FSH will improve our
      understanding of the failure of follicle development in subsets of patients with infertility,
      such as polycystic ovary syndrome, in which FSH levels are normal but follicles fail to
      develop. Study of FSH control will also help us understand the failure of negative feedback
      on FSH, which can result in multiple follicular development and multiple gestation and its
      associated costs and risks. Thus, these studies may afford new therapeutic options for
      conception in infertile patients while simultaneously providing new methods to avoid the
      risks of multiple gestations.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 21, 2004</start_date>
  <primary_completion_date type="Actual">June 29, 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a physiologic study designed to investigate the relative roles of estradiol and inhibin A or inhibin B in the control of FSH secretion during normal menstrual cycles using an aromatase inhibitor. Subjects serve as their own control with no intervention in cycle 1 and letrozole administration in cycle 2. Subjects are studied in the early follicular phase or the late follicular phase.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FSH Level</measure>
    <time_frame>EFP: average of menstrual cycle day 6 in the EFP; LFP: average of 2 days after follicle size of 16 mm</time_frame>
    <description>Difference in FSH peak following letrozole administration compared with control cycle</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Aromatase inhibitor EFP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole administration (20 mg) on day 2-4 (EFP; early follicular phase) of cycle 2 and
Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aromatase inhibitor LFP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole administration (20 mg daily x 2) at follicle size of &gt; 16 mm (LFP; late follicular phase) in cycle 2.
Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole 20 mg orally one time</description>
    <arm_group_label>Aromatase inhibitor EFP</arm_group_label>
    <arm_group_label>Aromatase inhibitor LFP</arm_group_label>
    <other_name>aromatase inhibitor</other_name>
    <other_name>Femara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NAL-GLU GnRH antagonist</intervention_name>
    <description>5 mcg/kg of the NAL-GLU GnRH antagonist subcutaneously</description>
    <arm_group_label>Aromatase inhibitor EFP</arm_group_label>
    <arm_group_label>Aromatase inhibitor LFP</arm_group_label>
    <other_name>GnRH antagonist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy Normal Subjects will meet the following criteria:

          -  18 to 35 years of age

          -  good general health

          -  on no medications including any hormonal drug products for at least 3 months before
             the study

          -  regular menstrual cycles every 25-35 days with ovulation documented by a luteal phase
             progesterone &gt; 3 ng/ml

          -  no evidence of androgen excess

          -  normal TSH, prolactin and hemoglobin

          -  use of double-barrier contraception, permanent sterilization or abstinence during the
             cycle of study.

          -  Negative pregnancy test (serum) at the beginning of each cycle of study

          -  Normal Liver Function Test

        Exclusion Criteria:

          -  History of liver and/or kidney disease

          -  Substance or alcohol abuse

          -  Hormone dependent neoplasia including breast cancer

          -  Women who are trying to become pregnant
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet E Hall, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reproductive Endocrine Unit, Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2006</study_first_submitted>
  <study_first_submitted_qc>July 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2006</study_first_posted>
  <results_first_submitted>March 16, 2017</results_first_submitted>
  <results_first_submitted_qc>March 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 27, 2017</results_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Janet E. Hall, MD</investigator_full_name>
    <investigator_title>Associate Physician</investigator_title>
  </responsible_party>
  <keyword>GnRH deficiency</keyword>
  <keyword>GnRH antagonist</keyword>
  <keyword>Letrozole</keyword>
  <keyword>GnRH</keyword>
  <keyword>FSH</keyword>
  <keyword>LH</keyword>
  <keyword>Inhibins</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
    <mesh_term>LHRH, N-Ac-2-Nal(1)-4-Cl-Phe(2)-3-Pal(3)-Arg(5)-Glu(6)-AlaNH2(10)-</mesh_term>
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Once published, de-identified individual level data will be shared upon request to the PI.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Four subjects did not meet inclusion criteria (2 had increased prolactin, 2 had abnormal cycles) and were excluded after screening and before assignment to treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aromatase Inhibitor EFP</title>
          <description>Letrozole administration (20 mg) on day 2-4 (EFP; early follicular phase) of cycle 2 and
Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted.
Letrozole: Letrozole 20 mg orally one time
NAL-GLU GnRH antagonist: 5 mcg/kg of the NAL-GLU GnRH antagonist subcutaneously</description>
        </group>
        <group group_id="P2">
          <title>Aromatase Inhibitor LFP</title>
          <description>Letrozole administration (20 mg daily x 2) at follicle size of &gt; 16 mm (LFP; late follicular phase) in cycle 2.
Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted.
Letrozole: Letrozole 20 mg orally one time
NAL-GLU GnRH antagonist: 5 mcg/kg of the NAL-GLU GnRH antagonist subcutaneously</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aromatase Inhibitor EFP</title>
          <description>Letrozole administration (20 mg) on day 2-4 (EFP; early follicular phase) of cycle 2 and
Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted.
Letrozole: Letrozole 20 mg orally one time
NAL-GLU GnRH antagonist: 5 mcg/kg of the NAL-GLU GnRH antagonist subcutaneously</description>
        </group>
        <group group_id="B2">
          <title>Aromatase Inhibitor LFP</title>
          <description>Letrozole administration (20 mg daily x 2) at follicle size of &gt; 16 mm (LFP; late follicular phase) in cycle 2.
Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted.
Letrozole: Letrozole 20 mg orally one time
NAL-GLU GnRH antagonist: 5 mcg/kg of the NAL-GLU GnRH antagonist subcutaneously</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.2" spread="5"/>
                    <measurement group_id="B2" value="28.5" spread="4.2"/>
                    <measurement group_id="B3" value="27.9" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FSH Level</title>
        <description>Difference in FSH peak following letrozole administration compared with control cycle</description>
        <time_frame>EFP: average of menstrual cycle day 6 in the EFP; LFP: average of 2 days after follicle size of 16 mm</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aromatase Inhibitor EFP</title>
            <description>Letrozole administration (20 mg) on day 2-4 (EFP; early follicular phase) of cycle 2 and
Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted.
Letrozole: Letrozole 20 mg orally one time
NAL-GLU GnRH antagonist: 5 mcg/kg of the NAL-GLU GnRH antagonist subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Aromatase Inhibitor LFP</title>
            <description>Letrozole administration (20 mg daily x 2) at follicle size of &gt; 16 mm (LFP; late follicular phase) in cycle 2.
Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted.
Letrozole: Letrozole 20 mg orally one time
NAL-GLU GnRH antagonist: 5 mcg/kg of the NAL-GLU GnRH antagonist subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>FSH Level</title>
          <description>Difference in FSH peak following letrozole administration compared with control cycle</description>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.25" spread="2.42"/>
                    <measurement group_id="O2" value="8.71" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aromatase Inhibitor EFP</title>
          <description>Letrozole administration (20 mg) on day 2-4 (EFP; early follicular phase) of cycle 2 and
Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted.
Letrozole: Letrozole 20 mg orally one time
NAL-GLU GnRH antagonist: 5 mcg/kg of the NAL-GLU GnRH antagonist subcutaneously</description>
        </group>
        <group group_id="E2">
          <title>Aromatase Inhibitor LFP</title>
          <description>Letrozole administration (20 mg daily x 2) at follicle size of &gt; 16 mm (LFP; late follicular phase) in cycle 2.
Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted.
Letrozole: Letrozole 20 mg orally one time
NAL-GLU GnRH antagonist: 5 mcg/kg of the NAL-GLU GnRH antagonist subcutaneously</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Janet Hall</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-877-1112</phone>
      <email>jehall@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

